Celldex's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy with seven company-led clinical trials across five product candidates, including a pivotal study in triple negative breast cancer and six Phase 1 and Phase 2 cancer immunotherapy combination trials in a range of difficult-to-treat indications, and a robust preclinical engine.